Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6442)
All Articles published online
|
Publishing Process of This Article
|
Jun 21, 2014 (publication date) through Dec 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Thompson JR. Emerging therapeutic options for the management of hepatitis C infection. World J Gastroenterol 2014; 20(23): 7079-7088 [PMID: 24966581 DOI: 10.3748/wjg.v20.i23.7079] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i23/7079.htm |
| Number | Citing Articles |
| 1 |
Amit Khatri, Sandeep Dutta, Thomas C. Marbury, Richard A. Preston, Lino Rodrigues, Haoyu Wang, Walid M. Awni, Rajeev M. Menon. Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment. Clinical Pharmacokinetics 2017; 56(2): 153 doi: 10.1007/s40262-016-0429-9
|
| 2 |
Bruno Pozzetto, Meriam Memmi, Olivier Garraud, Xavier Roblin, Philippe Berthelot. Health care-associated hepatitis C virus infection. World Journal of Gastroenterology 2014; 20(46): 17265-17278 doi: 10.3748/wjg.v20.i46.17265
|
| 3 |
Sven Mensing, Akshanth R. Polepally, Denise König, Amit Khatri, Wei Liu, Thomas J. Podsadecki, Walid M. Awni, Rajeev M. Menon, Sandeep Dutta. Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies. The AAPS Journal 2016; 18(1): 270 doi: 10.1208/s12248-015-9846-1
|
| 4 |
Matthew Ronan. Hepatitis C in Hospital Medicine. Hospital Medicine Clinics 2015; 4(2): 163 doi: 10.1016/j.ehmc.2014.11.003
|
| 5 |
Cássio Marques Perlin, Vinicius Lins Ferreira, Helena Hiemisch Lobo Borba, Astrid Wiens, Cláudia Alexandra Pontes Ivantes, Luana Lenzi, Roberto Pontarolo. Quality of life in Brazilian patients with treated or untreated chronic hepatitis C. Revista do Instituto de Medicina Tropical de São Paulo 2017; 59(0) doi: 10.1590/s1678-9946201759081
|
| 6 |
Akshanth R. Polepally, Sven Mensing, Amit Khatri, Denise Beck, Wei Liu, Walid M. Awni, Rajeev M. Menon, Sandeep Dutta. Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies. Clinical Pharmacokinetics 2016; 55(9): 1091 doi: 10.1007/s40262-016-0385-4
|
| 7 |
N.A. Meanwell. Comprehensive Medicinal Chemistry III. 2017; : 553 doi: 10.1016/B978-0-12-409547-2.12406-0
|